

The Manager
Companies Announcement Platform
SIM Venture Securities Exchange

20 July 2012

Telezon produces 14,500 Blunt SoloFlow[®] needle samples with CoreIT[®] Technology

HIGHLIGHTS:

- **14,500 Blunt SoloFlow[®] Cannula produced from small (4-fold) volume production tool**
-

The Board of Telezon[®] Limited ("the Company") continues to realise milestones for its most recent product, the Blunt SoloFlow[®] needle ("BSF"). The Company is pleased to announce that two needle lengths have been successfully produced using its unique and patented CoreIT[®] moulding technology, with a total of 14,500 samples produced over 24 hours.

Before Telezon scales up their production to higher volumes, there are several measures to be taken to ensure a safe and high quality production for their needles – one of which is the testing of the machine and equipment in small batches. Telezon has commenced this testing with successful results. In the last 24 hours, Telezon has conducted three batches:

- Batch 1 (uninterrupted run): 2,500 BSF needles of 25mm in length
- Batch 2 (uninterrupted run): 2,500 BSF needles of 30mm in length
- Batch 3 (uninterrupted run): 12,000 BSF needles of 30mm in length

Verification and validation tests for regulatory certifications such as FDA and CE Mark registration will be part of the critical next steps. This will enable Telezon's BSF to be sold in Europe and other foreign markets.

Realised funds from the current capital raising will help accelerate commercialisation of the Company's Blunt SoloFlow[®] needle.

For and on behalf of Telezon Limited,

Dr Michelle Carr
Director & Co. Secretary
T: 61 03 9763 8605 F: 61 03 9763 2714

Please refer to our website for more detailed information on our products and technology. Telezon is listed on SIM Venture Securities Exchange [www.simvse.com.au] (SIM: TLZ).